Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into

Executive Summary

The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.

You may also be interested in...

Novartis Gets First-Mover Advantage With FDA Approval Of Cosentyx For Psoriasis

Secukinumab gets to market before competing IL-17 inhibitors from Lilly and AstraZeneca/Amgen are even filed for approval. Wall Street is expecting blockbuster sales for psoriasis agents that can improve upon the performance of TNF inhibitors.

Novartis’ Secukinumab Sails Through Advisory Panel, Bodes Well For IL-17 Class

Unanimous advisory committee vote positions Novartis’ secukinumab to beat Lilly and Amgen/AstraZeneca competitors to market; panel supportive of Novartis’ preferred dose, letting other dosing issues be further explored post-market.

Secukinumab Phase III Data Look Reassuring Ahead Of Advisory Committee Review

Efficacy results look solid in pair of Phase III trials published in NEJM, but some question whether a double dose adds enough to get approval. Investigators note prevalence of Candida infections in patients on the Novartis drug.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts